Jazeta (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycemic control when combined with diet and exercise.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across multiple regions and adherence to local import requirements.

Jazeta (sitagliptin hydrochloride) is used in the DPP‑4 inhibitor class to manage hyperglycemia in type 2 diabetes.

Type 2 diabetes mellitus: improves glycemic control as an adjunct to diet and exercise, alone or with other antidiabetic agents. Inadequate control on metformin: provides additional glucose‑lowering effect when added to metformin therapy. Combination with sulfonylureas: enhances insulin secretion while reducing the risk of hypoglycemia compared with sulfonylurea monotherapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms such as sore throat or congestion. - Diarrhea: loose stools that are usually self‑limiting. - Hypoglycemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Elevated liver enzymes: abnormal hepatic function tests. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating therapy, consider the following precautions: - Renal impairment: dose adjustment may be required based on renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: avoid or monitor closely for recurrent episodes. - Concurrent insulin or sulfonylureas: increased risk of hypoglycemia; monitor glucose levels. - Elderly patients: assess renal function regularly as clearance may decline. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Jazeta may interact with other medicines as follows:

Major Interactions (Avoid): - Insulin: combined use can cause severe hypoglycemia. - Sulfonylureas: additive risk of low blood glucose. - Strong CYP3A4 inhibitors: may increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glycemic control; monitor blood glucose. - ACE inhibitors: monitor renal function when used together. - Rifampin: may reduce sitagliptin plasma concentrations, potentially diminishing efficacy.